Pre-Market Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros
LONDON, September 25, 2013
LONDON, September 25, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Tuesday, September 24, 2013, the U.S. equity market ended on a mixed note.
The S&P 500 and the Dow Jones Industrial Average fell by 0.26% and 0.43%,
respectively, while the NASDAQ Composite gained 0.08%. Shares in the
healthcare sector ended lower, even as the broader market fluctuated between
gains and losses. The major movers in the industry included Dendreon
Corporation (NASDAQ: DNDN), Stryker Corporation (NYSE: SYK), Novartis AG
(NYSE: NVS), and Repros Therapeutics Inc. (NYSE: RPRX). AAAResearchReports.com
initiated preliminary technical research on DNDN, SYK, NVS, and RPRX. These
free reports are accessible by signing today at:
Shares in Dendreon Corp. fell sharply on Tuesday, extending the losses from
the previous trading session. The company's shares ended the day at $2.98,
which is 1.81% lower than the previous day's price of $3.04. The company's
shares vacillated between $2.97 and $3.07 during the trading session. A total
of 2.44 million shares were traded, which is below the daily average volume of
4.51 million. Despite Tuesday's sharp decline, Dendreon Corp.'s stock has
advanced 2.41% in the last one month, compared to a gain of 2.04% in the S&P
500 during the same period. Additionally, the company's shares are trading
below their 50-day and 200-day moving averages of $3.64 and $4.66,
respectively. The free technical analysis on DNDN is available by signing up
Stryker Corp.'s stock fell by 0.52% on Tuesday, even as the broader market
ended on a mixed note. The company's shares closed the day at $70.83 after
oscillating between $70.77 and $71.45. A total of 1.05 million shares were
traded, which is below the daily average volume of 1.19 million. Despite
Tuesday's pullback, the company's shares have advanced 3.72% in the last one
month and 9.37% in the previous three months, outperforming the S&P 500 which
has gained 2.04% and 7.90% during the respective periods. Further, Stryker
Corp.'s stock is trading near its 52-week high of $71.94 as well as above its
50-day and 200-day moving averages of $69.97 and $65.21, respectively.
Register now to download free research on SYK at:
Shares in Novartis AG edged lower on Tuesday, reversing all of the gains from
the previous trading session. The company's shares traded between $76.17 and
$76.71 before finishing the day 0.48% lower at $76.37. A total of 0.71 million
shares were traded, which is below the daily average volume of 1.39 million.
Despite Tuesday's losses, the company's stock is up 1.26% in the last one
month and 11.62% in the previous three months, compared to a gain of 2.04% and
7.90% in the S&P 500 during the respective periods. Moreover, Novartis AG's
stock is trading near its 52-week high of $77.02 as well as above its 50-day
and 200-day moving averages of $73.95 and $70.70, respectively. A free report
on NVS can be accessed by registering at:
On Tuesday, Repros Therapeutics Inc.'s stock fell sharply after hitting a new
52-week high of $29.79. The company's shares closed the day at $28.08, down
1.09% from the previous day's price of $28.39. A total of 0.94 million shares
were traded, which is more than the daily average volume of 0.66 million.
Despite Tuesday's sharp decline, Repros Therapeutics Inc.'s shares have
rallied 49.04% in the last one month and 59.64% in the previous three months,
outperforming the S&P 500 which has gained 2.04% and 7.90% during the
respective periods. Furthermore, the company's stock is currently trading
above its 50-day and 200-day moving averages of $21.13 and $16.86,
respectively. Register with AAA Research Reports and download research on RPRX
for free at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126, Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.